An enhanced immune response against G250, induced by a heterologous DNA prime‑protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant

Sun,Zeqiang; Liu,Bo; Ruan,Xiyun; Liu,Qingyong

doi:10.3892/mmr.2014.2537

An enhanced immune response against G250, induced by a heterologous DNA prime‑protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant

Authors:
- Zeqiang Sun
- Bo Liu
- Xiyun Ruan
- Qingyong Liu
View Affiliations

Affiliations: Department of Urinary Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shangdong 250013, P.R. China, Intensive Care Unit, Affiliated Hospital of Jinin Medical College, Jining, Shandong 272000, P.R. China, Department of Neurology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: September 4, 2014 https://doi.org/10.3892/mmr.2014.2537
Pages: 2657-2662

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The heterologous DNA prime‑protein boost vaccination approach has been widely applied as an immune treatment for carcinoma. However, inefficient delivery of DNA remains a major issue. In the present study, polyethyleneimine (PEI) was used as a DNA vector carrier to improve the transfection efficiency of the DNA vaccine and stimulate the humoral and cellular immunity against the renal carcinoma‑associated antigen G250. A protein vaccine was included in the immunization strategy in order to produce a prime‑boost effect. A DNA plasmid encoding an antigen G250 fragment was constructed and complexed with PEI. A protein vaccine against G250 was expressed in BL21 (DE3) Escherichia coli cells, by transformation with a pET28a(+)/C‑G250 plasmid. The protein was purified using a nickel‑nitriloacetic acid purification system. The in vitro transfection efficiency of the DNA vaccine was analyzed in HEK293 human endothelial kidney cells. The in vitro transfection efficiency in HEK293 cells was highest 48 h after transfection. Furthermore, mice were primed with 200 µg pVAX1/C‑250 plasmid complexed with PEI, and boosted using 50 µg of purified C‑G250 protein. In order to evaluate the immune response the antibody titer, splenocyte response, and interferon‑γ levels from CD8+ T‑cell splenocytes were analyzed using ELISA, lymphocyte proliferation or enzyme‑linked immunosorbent spot assays. Firstly, the pVAX1/C‑G250 plasmid was shown to be constructed successfully. As compared with the DNA group, the antibody titer, lymphocyte proliferation percentage, and cytokine production level induced by the DNA‑PEI and DNA‑PEI+C‑G250 groups were significantly higher. Furthermore, the DNA‑PEI+C‑G250 group exhibited the strongest humoral and cellular response. Owing to the adjuvant effect of PEI, the pVAX1/C‑G250‑PEI prime plus C‑G250 protein boost regimen could induce a strong immune response, and has been proved to be a potent vaccine candidate against renal cell carcinoma.

View Figures

View References

1	Awakura Y, Ito N, Nakamura E, et al: Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett. 241:59–63. 2006. View Article : Google Scholar : PubMed/NCBI
2	Dutcher JP: Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol. 5:338–353. 2013. View Article : Google Scholar : PubMed/NCBI
3	Tostain J, Li G, Gentil-Perret A and Gigante M: Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer. 46:3141–3148. 2010. View Article : Google Scholar : PubMed/NCBI
4	Stadick H, Stockmeyer B, Kühn R, et al: Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? J Urol. 167:707–712. 2002. View Article : Google Scholar : PubMed/NCBI
5	Li G, Feng G, Gentil-Perret A, Genin C and Tostain J: CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy. Clin Exp Metastasis. 24:149–155. 2007. View Article : Google Scholar : PubMed/NCBI
6	Muselaers S, Mulders P, Oosterwijk E, Oyen W and Boerman O: Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy. 5:489–495. 2013. View Article : Google Scholar : PubMed/NCBI
7	Vissers JL, De Vries IJ, Engelen LP, et al: Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int J Cancer. 100:441–444. 2002. View Article : Google Scholar
8	Vissers JL, De Vries IJ, Schreurs MW, et al: The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 59:5554–5559. 1999.PubMed/NCBI
9	Xiao Y, Gao J, Gao K, et al: Prokaryotic expression, purification and antigenicity identification of human renal cell carcinoma-associated antigen G250. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 29:269–272. 2013.(In Chinese).
10	Liu B, Sun Z, Liu Q, et al: Construction and prokaryotic expression of recombinant gene G250 antigenic peptide-HBcAg and the immunogenicity analysis of the fusion protein. Journal of Xi’an Jiaotong University (Medical Sciences). 1:6–11. 2014.
11	Manoj S, Babiuk LA and van Drunen Littel-van den Hurk S: Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci. 41:1–39. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ada G: Vaccines and vaccination. N Engl J Med. 345:1042–1053. 2001. View Article : Google Scholar : PubMed/NCBI
13	Grant EV, Thomas M, Fortune J, Klibanov AM and Letvin NL: Enhancement of plasmid DNA immunogenicity with linear polyethylenimine. Eur J Immunol. 42:2937–2948. 2012. View Article : Google Scholar : PubMed/NCBI
14	Krishnamachari Y, Geary SM, Lemke CD and Salem AK: Nanoparticle delivery systems in cancer vaccines. Pharm Res. 28:215–236. 2011. View Article : Google Scholar : PubMed/NCBI
15	Demeneix B and Behr JP: Polyethylenimine (PEI). Adv Genet. 53PA:215–230. 2005. View Article : Google Scholar : PubMed/NCBI
16	Kichler A, Leborgne C, Coeytaux E and Danos O: Polyethylenimine-mediated gene delivery: a mechanistic study. J Gene Med. 3:135–144. 2001. View Article : Google Scholar : PubMed/NCBI
17	Ma YF and Yang YW: Delivery of DNA-based cancer vaccine with polyethylenimine. Eur J Pharm Sci. 40:75–83. 2010. View Article : Google Scholar : PubMed/NCBI
18	Bivas-Benita M, Bar L, Gillard GO, et al: Efficient generation of mucosal and systemic antigen-specific CD8+ T-cell responses following pulmonary DNA immunization. J Virol. 84:5764–5774. 2010. View Article : Google Scholar : PubMed/NCBI
19	Gaugler B, Brouwenstijn N, Vantomme V, et al: A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics. 44:323–330. 1996. View Article : Google Scholar : PubMed/NCBI
20	Brossart P, Stuhler G, Flad T, et al: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 58:732–736. 1998.
21	Kawagoe N, Shintaku I, Yutani S, et al: Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol. 164:2090–2095. 2000. View Article : Google Scholar : PubMed/NCBI
22	Li K, Gao H, Gao L, et al: Enhancement of humoral and cellular immunity in chickens against reticuloendotheliosis virus by DNA prime-protein boost vaccination. Vaccine. 31:1944–1949. 2013. View Article : Google Scholar : PubMed/NCBI
23	Li M, Jiang Y, Xu C, Zhang Z and Sun X: Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant. Int J Nanomedicine. 8:1843–1854. 2013.
24	Lan J, Gao Z, Xiong H, et al: Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination. Vaccine. 29:6894–6902. 2011. View Article : Google Scholar : PubMed/NCBI
25	Huang X, Xu J, Qiu C, et al: Mucosal priming with PEI/DNA complex and systemic boosting with recombinant TianTan vaccinia stimulate vigorous mucosal and systemic immune responses. Vaccine. 25:2620–2629. 2007. View Article : Google Scholar : PubMed/NCBI
26	Goula D, Becker N, Lemkine GF, et al: Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther. 7:499–504. 2000. View Article : Google Scholar : PubMed/NCBI
27	Wegmann F, Gartlan KH, Harandi AM, et al: Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. Nat Biotechnol. 30:883–888. 2012. View Article : Google Scholar : PubMed/NCBI